releasably pegylated il-2 mutein

Releasably pegylated IL-2 mutein is a modified version of Interleukin-2 (IL-2) designed to improve its therapeutic efficacy in immune-oncology. It features a releasable polyethylene glycol (PEG) conjugation that enhances its pharmacokinetic profile. This mutein is engineered to have dramatically decreased capability for binding to the IL-2 receptor alpha (IL-2Ra) subunit, which helps to selectively activate CD8+ T cells, including those residing in lymphoid organs and the tumor microenvironment, without inducing significant serious side effects. The drug aims to overcome the limitations of native IL-2, such as its short half-life and non-selective activation of immune cells, by promoting cytotoxic T lymphocyte (CTL) activity, particularly under acidic tumor microenvironment conditions. It is being investigated for its potential in treating solid tumors.